Camp4 Therapeutics CORP Schedule 13D activist filings

5AM Ventures entities and associated individuals have filed an amendment to their Schedule 13D, reporting changes in beneficial ownership and recent stock transactions for CAMP4 Therapeutics Corporation.

Polaris Partners entities and associated individuals have amended their Schedule 13D filing to reflect a decrease in their aggregate beneficial ownership of Camp4 Therapeutics Corporation's common stock.

5AM Ventures entities and associated individuals have amended their Schedule 13D filing, increasing their beneficial ownership in CAMP4 Therapeutics Corporation following a recent closing.

Enavate Sciences GP and Everest Aggregator have reduced their beneficial ownership in CAMP4 Therapeutics Corporation to 6.0% through recent open market sales.

Enavate Sciences and Everest Aggregator report a diluted beneficial ownership of 8.1% in CAMP4 Therapeutics Corporation following a private placement, alongside a director's resignation.

Polaris Partners and affiliated entities increased their beneficial ownership in Camp4 Therapeutics to 8.4% following a $50.1 million private placement.

5AM Ventures and affiliates increased their beneficial ownership in CAMP4 Therapeutics to 12.5% through a $4.5 million initial private placement.